

Annex – Curriculum Vitae Heikki Lanckriet, Ph.D. (including an overview on main activities)

Heikki Lanckriet, Ph.D.

born 1977 in Ypern, Belgium
Belgian
resident in Cambridge, United Kingdom

Education

1995-2000 M. Eng Chemical Engineering, University of Gent, Belgium
2001-2004 Ph.D. in Chemical Engineering, University of Cambridge, United Kingdom

Professional Career

2002-2005 Co-Founder and Chief Scientific Officer Novexin
2005-2008 Chief Operating Officer Novexin
2008-2016 Chief Executive Officer Expedeon Group
2016-2019 Chief Executive Officer Sygnis AG/Expedeon AG
since 2019 Chief Executive Officer 4basebio PLC

Main activities besides the Supervisory Board mandate

Mr. Lanckriet, Ph.D., has been Chief Executive Officer of 4basebio PLC, Cambridge, United Kingdom, the shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE), since 2019. He is also a member of the legally required Supervisory Board of Biofrontera AG, Leverkusen, Germany, and a member of comparable domestic and foreign control committees of the following commercial enterprises: 4basebio UK Ltd and 4basebio Discovery Limited, both Cambridge, United Kingdom; 4basebio SLU, Madrid, Spain; I2I Capital Limited, Cambridge, United Kingdom; KITHER BIOTECH S.R.L., Turin, Italy; and NeoPhore Ltd, Cambridge, United Kingdom.